Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 17.53B |
| Revenue (ttm) | 2.55B |
| Net Income (ttm) | 3.81B |
| Shares Out | 29.77M |
| EPS (ttm) | 126.20 |
| PE Ratio | 4.63 |
| Forward PE | 49.26 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $584.50 |
| Previous Close | $582.45 |
| Change ($) | 2.05 |
| Change (%) | 0.35% |
| Day's Open | 588.60 |
| Day's Range | 578.00 - 592.94 |
| Day's Volume | 242,319 |
| 52-Week Range | 309.38 - 689.00 |
Non-operating income not only overstates GAAP net income but could negatively impact Bio-Rad's ability to obtain additional financing.
Bio-Rad to Participate in Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwa...
Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Bio-Rad (BIO) delivered earnings and revenue surprises of 29.35% and 15.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 72.84% year over ye...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results...
Bio-Rad Laboratories (NYSE:BIO) unveils its next round of earnings this Thursday, February 11. Get prepared with Benzinga's ultimate preview for Bio-Rad Laboratories's Q4 earnings.
Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.
These are the stocks with the best value, fastest growth, and most momentum for February.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for...
These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.
If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwa...
"Why do you like tobacco stocks so much?" my colleague asked our boss, David Dreman (Trades, Portfolio), about two decades ago.
These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.
Perhaps you've seen the Energizer Bunny in a battery commercial. It is "still going" long after you'd expect it to fade.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook throu...
Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.
These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.
Is (BIO) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for November 13th
Value focused investors may want to consider the following stocks, since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted ...
As of late, it has definitely been a great time to be an investor in Bio-Rad Laboratories (BIO).
Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2020 Results - Earnings Call Transcript
Bio-Rad (BIO) delivered earnings and revenue surprises of 62.16% and 14.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Bio-Rad Laboratories (NYSE:BIO) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 86.34% year over year to $3.00, whi...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
Bio-Rad (BIO) Q3 earnings are expected to have benefited from strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Gains 16.2% Since September, Bullish Outlook Remains Strong
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for...
Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.
With four potential Covid-19 vaccine candidates from Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), AstraZeneca PLC (NYSE:AZN) and Johnson & Johnson (NYSE:JNJ) now in late-stage human tri...
These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.
Jefferies' Steven Desanctis on why investors should look beyond Big Tech
Steven Desanctis, Jefferies U.S. small mid-cap strategist managing director, joins 'Power Lunch' to discuss why investors can look to invest in names beyond Big Tech.
FCF has grown 159% YoY, however ROCE remains sluggish at only 3%, which we feel needs evidence of improvement into Q3.
Bio-Rad Laboratories (BIO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Ci...
Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.
Bio-Rad (BIO) delivered earnings and revenue surprises of 23.85% and 1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc.
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.
About BIO
Bio-Rad Laboratories develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques... [Read more...]
| Industry Medical Devices | Founded 1952 |
| CEO Norman Schwartz | Employees 8,000 |
| Stock Exchange NYSE | Ticker Symbol BIO |
Financial Performance
In 2020, BIO's revenue was $2.55 billion, an increase of 10.12% compared to the previous year's $2.31 billion. Earnings were $3.81 billion, an increase of 116.43%.
Analyst Forecasts
According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 752.50, which is an increase of 28.74% from the latest price.